ICON, a global provider of drug development solutions and services, reported an adjusted net income of $1,058.2 million for the full year 2023.
ICON's Financial Performance in 2023
ICON's financial results for the full year and fourth quarter of 2023 highlight its robust performance, particularly in terms of profitability. The "adjusted net income" figure represents the company's profit after certain adjustments, providing a clear picture of its core earnings.
Here’s a breakdown of ICON's key financial achievements in 2023:
| Period | Adjusted Net Income | Diluted Earnings Per Share (EPS) | Year-over-Year Increase in EPS |
|---|---|---|---|
| Full Year 2023 | $1,058.2 million | $12.79 | 8.9% |
| Q4 2023 | $287.5 million | $3.46 | 10.5% |
Key Highlights from 2023 Results
- Significant Growth: The full year adjusted net income of $1,058.2 million represents an increase of 8.9% compared to the prior year's adjusted earnings per share.
- Strong Quarter End: The fourth quarter of 2023 alone contributed $287.5 million to the adjusted net income, marking a 10.5% increase in adjusted earnings per share over Q4 2022.
- Per Share Earnings: In addition to the total net income, the company reported $12.79 in adjusted diluted earnings per share for the full year and $3.46 for the fourth quarter.
These figures underscore ICON's financial health and its capacity for sustained growth in the pharmaceutical and biotechnology research sectors. For more detailed information, you can refer to the official press release on ICON's Fourth Quarter and Full Year 2023 Results.
